Estimation of the Carbohydrate Moiety of von Willebrand Factor in the Plasma of Patients with Subtypes 2a and 2b of von Willebrand Disease

Summary

Von Willebrand disease (vWD) results from quantitative (types 1 and 3) or qualitative (type 2) deficiency of von Willebrand factor (vWF). This glycoprotein present in plasma is involved in platelet adhesion at the site of vascular injury and serves as the carrier of antihaemophilic A factor (FVIII). Whereas recent studies have identified mutations in patients suffering from type 2 vWD, the integrity of the carbohydrate moiety of vWF in these patients is still matter of debate. In order to analyse in the plasma milieu the carbohydrate content of plasma vWF from various well-characterized type 2 vWD patients, we developed a colorimetric assay in microtiter plate based on the use of peroxidase- conjugated lectins specific for either α 2-6 sialic acid or β 1-4 galactose. Removal of sialic acid from purified plasma vWF induced significant changes in the reactivity of both lectins. The analysis of various normal plasmas showed no influence of the blood groups and allowed us to compare various vWD patients. The reactivity of lectins for plasma vWFs from two type 2A and six type 2B vWD patients harbouring different mutations was not statistically different from that of a pool of normal plasmas. We conclude that the α 2-6 sialic acid and β 1-4 galactose content of plasma vWF is not altered in these patients affected with types 2A and 2B vWD.

• References

• 1 Meyer D, Girina JP. Von Willebrand factor: Structure and function. Thromb Haemost 1993; 70: 99-104
• 2 Titani K, Kumar S, Takio K, Ericsson LH, Wade RD, Ashida K, Walsh KA, Chopck MW, Sadler JH, Fujikawa K. Amino acid sequence of human von Willebrand factor. Biochem 1986; 25: 3171-3184
• 3 Debeire P, Montreuil J, Samor B, Mazurier C, Goudemand M, Van llalbeck H, Vliegenthart JF G. Structure determination of the major asparagine-linked sugar chain of human factor Vlll/von Willebrand factor. EEBS Lett 1983; 151: 22-26
• 4 Samor B, Michalski JC, Mazurier C, Goudemand M, De Waard P, Vliegenthart JP G, Strecker G, Montreuil J. Primary structure of the major O-glycosidically linked carbohydrate unit of human von Willebrand factor. Glycoconjugate J 1989; 6: 263-270
• 5 Ruggeri ZM, Zimmerman TS. The complex multimeric composition of factor Vlll/von Willebrand factor. Blood 1981; 57: 1140-1143
• 6 Sadler JE. A revised classification of von Willebrand disease. Thromb Haemost 1994; 71: 520-525
• 7 Ruggeri ZM, Zimmerman TS. Classification of von Willebrand disease. J Clin Lab Anal 1987; 1: 353-362
• 8 Gralnick HR, Coller BS, Sultan Y. Carbohydrate deficiency of the factor VIII/vW factor protein in vWD variants. Science 1976; 192: 56-59
• 9 Gralnick HR, Williams SB, McKcown LP. Von Willebrand’s disease with spontaneous platelet aggregation induced by abnormal plasma von Willebrand factor. J Clin Invest 1985; 76: 1522-1529
• 10 Gralnick HR, Sultan Y, Coller BS. Von Willebrand’s disease: combined qualitative and quantitative abnormalities. N Engl J Med 1977; 296: 1024-1030
• 11 Berkowitz S, Federici AB. Sialic acid prevents loss of large von Willebrand factor multimers by protecting against amino-terminal proteolytic cleavage. Blood 1988; 71: 947-952
• 12 Fulcher CA, Ruggeri ZM, Zimmerman TS. Isoelectric focusing of human von Willebrand factor in urea-agarose gels. Blood 1983; 61: 304-310
• 13 De Marco L, Mazzucato M, Grazia Del Ben M, Budde U, Federici AB, Girolami A, Ruggeri TM. Type IIB von Willebrand factor with normal sialic acid content induces platelet aggregation in the absenceof ristocetin. Role of platelet activation, fibrinogen and two distinct membrane receptors J Clin Invest 1987; 80: 475-482
• 14 Ginsburg D, Sadler JE. Von Willebrand disease: a database of point mutations, insertions, and deletions. Thromb Haemost 1993; 69: 177-184
• 15 Mazurier C, Parquet-Gernez A, Goudemand M. Dosage de l’antigène lié au facteur VIII par la technique ELISA. Intérêt dans l’étude de la maladie de Willebrand Path Biol 1977; 25: 18-24
• 16 Jorieux S, de Romeuf C, Samor B, Goudemand M, Mazurier C. Characterization of a monoclonal antibody to von Willebrand factor as a potent inhibitor of ristocetin-mediated platelet interaction and platelet adhesion. Thromb Haemost 1987; 57: 278-282
• 17 Mazurier C. Purification, Biochemistry and structure/function relationships of vWF. In: FVIII-von Willebrand factor. Biochemical, methodological, and functional aspects. Seghatchian MJ, Savidge GF. eds CRC Press; 1989. 1 41-82
• 18 Federici AB, de Romeuf C, De Groot PG, Samor B, Lombardi R, D’Alessio P, Mazurier C, Sixma JJ, Mannucci PM, Sixma JJ. Adhesive properties of the carbohydrate-modified von Willebrand factor (CHO-vWF). Blood 1988; 71: 947-52
• 19 Warren C. The thiobarbituric acid assay for sialic acids. J Biol Chem 1959; 234: 1971-1975
• 20 Mikami S, Veda M, Yasui M, Takahashi Y, Nishino M, Fukui H. Heterogeneity of sugar composition of factor VUI/von Willebrand factor in vWD: analysis by crossed affino-immuno-electrophoresis using lectin (Ricinus communis agglutinin-120). Thromb Haemost 1983; 49: 87-90
• 21 Krauss JS, Baisden CR. Factor VIII related antigen-concanavalin A binding in plasma and serum. Thromb Res 1985; 37: 477-480
• 22 Samor B, Mazurier C, Goudemand M, Debeire P, Fournet B, Montreuil J. Preliminary results on the carbohydrate moiety of factor VUI/von Willebrand factor (FVIII/vWF). Thromb Res 1982; 22: 81-89
• 23 Sodetz JM, Paulson SV, Pizzo SV, McKee PA. Carbohydrate on human factor VUI/von Willebrand factor. Impairment of function by removal of specific galactose residues J Biol Chem 1978; 253: 7202-7206
• 24 Samor B, Michalski JC, Debray H, Mazurier C, Goudemand M, Van Halbeeck H, Vliegenthart JF G, Montreuil J. Primary structure of a new tetraantennary glycan of N-acetylactosaminic type isolated from human factor VUI/von Willebrand factor. Eur J Biochem 1986; 158: 295-298
• 25 Federici AB, Elder JH, De Marco L, Ruggeri ZM, Zimmerman TS. Carbohydrate moiety of von Willebrand factor is not necessary for maintaining multimeric structure and ristocetin cofactor activity but protects from proteolytic degradation. J Clin Invest 1984; 74: 2049-2055
• 26 Carew JA, Quinn SM, Stoddart JH, Lynch DC. O-linked carbohydrate of recombinant von Willebrand factor influences ristocetin-induced binding to platelet glycoprotein lb. J Clin Invest 1992; 90: 2258-2267
• 27 Vink T, Schiphorst ME, Sixma J. Expression of recombinant von Willebrand factor lacking specific N glycosylation sites. Thromb Haemost 1993; 69 Abstract 2343